Abbott Laboratories (NYSE:ABT) Q4 2023 Earnings Conference Call January 24, 2024 9:00 AM ET Company Participants Mike Comilla - Vice President, Investor Relations Robert Ford - Chairman and Chief Executive Officer Philip Boudreau - Senior Vice President, Finance and Chief Financial Officer Conference Call Participants Larry Biegelsen - Wells Fargo Joshua Jennings - TD Cowen Marie Thibault - BTIG Robbie Marcus - JPMorgan Danielle Antalffy - UBS Joanne Wuensch - Citibank Vijay Kumar - Evercore ISI Travis Stee ...

Abbott Laboratories (ABT) reported fourth-quarter 2023 adjusted earnings per share (EPS) of $1.19, in line with the Zacks Consensus Estimate. The adjusted figure increased 15.5% from the prior-year quarter’s level. The quarter’s adjustments include 28 cents of certain non-recurring items.GAAP EPS came in at 91 cents, which increased 54.2% year over year.Full-year adjusted EPS was $4.44, reflecting a 16.9% decline from the 2022 figure. The figure, too, however, came in line with the Zacks Consensus Estimate. ...

Pre-market futures are back up again this morning, with a series of Q4 earnings reports greeting us in the early morning hours, with the only major economic reads — S&P flash Services and Manufacturing PMI — expected after the opening bell. Both the Dow and Nasdaq are up +158 points at this hour, +0.41% and +0.90%, respectively, while the S&P 500 is +0.58% and the small-cap Russell 2000 is double that: +1.19%.Zacks Rank #2 (Buy)-rated Big Pharma staple Abbott Labs (ABT) met bottom-line expectations in its Q ...

For the quarter ended December 2023, Abbott (ABT) reported revenue of $10.24 billion, up 1.5% over the same period last year. EPS came in at $1.19, compared to $1.03 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $10.17 billion, representing a surprise of +0.71%. The company has not delivered EPS surprise, with the consensus EPS estimate being $1.19.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compa ...

Abbott (ABT) came out with quarterly earnings of $1.19 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $1.03 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this maker of infant formula, medical devices and drugs would post earnings of $1.10 per share when it actually produced earnings of $1.14, delivering a surprise of 3.64%.Over the last four quarters, the company has surpassed consensus EPS estimates three tim ...

About this content About William Farrington William kickstarted his career as a researcher and reporter for a global legal publication, covering everything from public law to M&A. Before moving to Proactive Investors, he worked as a reporter for a major fintech company with a focus on cryptocurrency and blockchain technology. Harking from Queensland, Australia, William obtained first-class honours in journalism and media from Birkbeck University before going on to complete an MA in creative and critical ...

智通财经APP获悉，周三美股盘前，雅培(ABT.US)公布了第四季度业绩。在医疗设备和营养部门表现强劲的推动下，该公司Q4营收实现超预期，不过，该公司提供的全年业绩不及市场预期，这导致该股盘前跌逾2%。 数据显示，雅培Q4营收同比增长1.5%至102.4亿美元，超过了分析师平均预期的101.86亿美元，不包括COVID-19检测相关的有机销售额增长了11%。调整后每股收益为1.19美元，与分析师预期一致。 按业务划分，医疗设备部门营收为44.4亿美元，同比增长17.5%，高于市场预期的43.3亿美元，其中，FreeStyle Libre连续血糖监测仪的销售额增长25.5%，与COVID检测相关的销售额为2.88亿美元，低于上年同期的10.7亿美元。 营养业务营收为20.4亿美元，同比增长12%。诊断业务营收为25.3亿美元，同比下降23%，与市场预期一致。仿制药业务销售额为12.2亿美元，同比增长0.5%，但低于市场预期的13.2亿美元;糖尿病护理销售额达到15.5亿美元，同比增长22%，高于预期的15.2亿美元。 在COVID检测业务急剧下降后，雅培希望重新将重心放在其核心领域，寻求通过其连续血糖监测仪等产 ...

Abbott Laboratories (NYSE: ABT) is trading down in premarket on Wednesday even though it reported solid results for its fiscal fourth quarter.Why is Abbott stock down on Wednesday?Copy link to sectionInvestors seem unhappy also because the healthcare company issued a not-so encouraging guidance for the future. Abbott now forecasts its sales to climb up to 10% (excluding COVID sales) on $4.50 to $4.70 of per-share earnings in fiscal 2024. Analysts, in comparison, had called for $4.63 a share. Robert Ford – i ...

Why bother talking about safe-haven stocks for a recession when we already dodged that bullet last year? Tell me you haven’t seen a Friday the 13th movie without telling me. Any horror film aficionado knows that if you ever survive the maniacal clutches of Jason Voorhees, it ain’t over until the credits roll. Till then, you should probably avoid any bodies of water.It’s the same principle with so-called recession stocks. No one’s hoping for an economic downturn – I think we’ve all had our fair share of dram ...

Several expansive companies are expected to post stellar quarterly growth when they report Q4 earnings on Wednesday, January 24.Having a dominant presence in their respective markets here are a few top-rated Zacks stocks to consider as their quarterly results approach.The Progressive (PGR) : Home and auto insurance giant Progressive shouldn’t be overlooked ahead of its Q4 results with earnings projected to soar 58% to $2.38 per share versus $1.50 a share in the comparative quarter. Fourth quarter sales are ...